Skip to main content
Top
Published in: Clinical Rheumatology 11/2020

01-11-2020 | Polymyositis | Original Article

Temporal relationship between idiopathic inflammatory myopathies and malignancies and its mortality: a nationwide population-based study

Authors: Yoon-Kyoung Sung, Sun-Young Jung, Hyoungyoung Kim, Seongmi Choi, Seul Gi Im, Eom Ji Cha, Eun Jin Jang, Dae-Hyun Yoo, Soo-Kyung Cho

Published in: Clinical Rheumatology | Issue 11/2020

Login to get access

Abstract

Objectives

To examine the temporal relationship between malignancies and idiopathic inflammatory myopathies (IIMs) and its impact on mortality.

Methods

A retrospective cohort for IIM patients was conducted using the Korean National Health Insurance Service databases. We observed more than 5 years before and after the diagnosis of IIM (2002~2016) to identify IIM patients who developed any malignancy and classified these patients into two groups: the cancer-associated myositis (CAM) group, who developed malignancy within 3 years before or after the diagnosis of IIM and the cancer-not-associated myositis (CNAM) group, who developed malignancy beyond 3 years of IIM onset. The survival rates of the two groups were compared.

Results

We identified 1072 incident cases of IIM between 2007 and 2011. A total 225 patients of these patients were diagnosed with malignancy. The development of malignancy was frequent within 1 year before and after the time of IIM diagnosis. The common sites of malignancies in the CAM group differed from those in the CNAM group: the lung, hematologic malignancy, and the liver were common in both groups, but thyroid and oropharynx followed them in CAM while prostate, stomach, breast, and thyroid followed them in CNAM. CAM patient mortality was worse compared with CNAM patients (log-rank test, p < 0.01).

Conclusions

Among IIM patients with malignancy, common sites of malignancy were different between the CAM and CNAM groups, and patients with CAM had poor prognosis compared with CNAM patients.
Key Points
The malignancies commonly occurred in incident idiopathic inflammatory myopathy (IIM) patients, especially within 1 year before and after the initial IIM diagnosis.
Patients with malignancy had poor survival compared with patients without malignancy.
Among the IIM patients with malignancy, patients who developed malignancy within 3 years of IIM diagnosis (cancer-associated myositis, or CAM, group) showed higher mortality than cancer-not-associated myositis, CNAM group.
We also found that the common types of malignancy were different between the CAM and CNAM groups.
Appendix
Available only for authorised users
Literature
1.
go back to reference Rider LG, Miller FW (2011) Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies. JAMA 305(2):183–190CrossRef Rider LG, Miller FW (2011) Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies. JAMA 305(2):183–190CrossRef
2.
go back to reference Lundberg IE, de Visser M, Werth VP (2018) Classification of myositis. Nat Rev Rheumatol 14:269–278CrossRef Lundberg IE, de Visser M, Werth VP (2018) Classification of myositis. Nat Rev Rheumatol 14:269–278CrossRef
3.
go back to reference Marie I, Hachulla E, Cherin P, Dominique S, Hatron PY, Hellot MF et al (2002) Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 47(6):614–622CrossRef Marie I, Hachulla E, Cherin P, Dominique S, Hatron PY, Hellot MF et al (2002) Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 47(6):614–622CrossRef
4.
go back to reference Tiniakou E, Mammen AL (2017) Idiopathic inflammatory myopathies and malignancy: a comprehensive review. Clin Rev Allergy Immunol 52(1):20–33CrossRef Tiniakou E, Mammen AL (2017) Idiopathic inflammatory myopathies and malignancy: a comprehensive review. Clin Rev Allergy Immunol 52(1):20–33CrossRef
5.
go back to reference Ungprasert P, Leeaphorn N, Hosiriluck N, Chaiwatcharayut W, Ammannagari N, Raddatz DA (2013) Clinical features of inflammatory myopathies and their association with malignancy: a systematic review in Asian population. ISRN Rheumatol 2013:509354CrossRef Ungprasert P, Leeaphorn N, Hosiriluck N, Chaiwatcharayut W, Ammannagari N, Raddatz DA (2013) Clinical features of inflammatory myopathies and their association with malignancy: a systematic review in Asian population. ISRN Rheumatol 2013:509354CrossRef
6.
go back to reference Airio A, Pukkala E, Isomaki H (1995) Elevated cancer incidence in patients with dermatomyositis: a population based study. J Rheumatol 22(7):1300–1303PubMed Airio A, Pukkala E, Isomaki H (1995) Elevated cancer incidence in patients with dermatomyositis: a population based study. J Rheumatol 22(7):1300–1303PubMed
7.
go back to reference Limaye V, Luke C, Tucker G, Hill C, Lester S, Blumbergs P, Roberts-Thomson P (2013) The incidence and associations of malignancy in a large cohort of patients with biopsy-determined idiopathic inflammatory myositis. Rheumatol Int 33(4):965–971CrossRef Limaye V, Luke C, Tucker G, Hill C, Lester S, Blumbergs P, Roberts-Thomson P (2013) The incidence and associations of malignancy in a large cohort of patients with biopsy-determined idiopathic inflammatory myositis. Rheumatol Int 33(4):965–971CrossRef
8.
go back to reference Casciola-Rosen L, Nagaraju K, Plotz P, Wang K, Levine S, Gabrielson E, Corse A, Rosen A (2005) Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 201(4):591–601CrossRef Casciola-Rosen L, Nagaraju K, Plotz P, Wang K, Levine S, Gabrielson E, Corse A, Rosen A (2005) Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 201(4):591–601CrossRef
9.
go back to reference Kasuya A, Hamaguchi Y, Fujimoto M, Tokura Y (2013) TIF1gamma-overexpressing, highly progressive endometrial carcinoma in a patient with dermato-myositis positive for malignancy-associated anti-p155/140 autoantibody. Acta Derm Venereol 93(6):715–716CrossRef Kasuya A, Hamaguchi Y, Fujimoto M, Tokura Y (2013) TIF1gamma-overexpressing, highly progressive endometrial carcinoma in a patient with dermato-myositis positive for malignancy-associated anti-p155/140 autoantibody. Acta Derm Venereol 93(6):715–716CrossRef
10.
go back to reference Kang EH, Lee SJ, Ascherman DP, Lee YJ, Lee EY, Lee EB, Song YW (2016) Temporal relationship between cancer and myositis identifies two distinctive subgroups of cancers: impact on cancer risk and survival in patients with myositis. Rheumatology (Oxford) 55(9):1631–1641CrossRef Kang EH, Lee SJ, Ascherman DP, Lee YJ, Lee EY, Lee EB, Song YW (2016) Temporal relationship between cancer and myositis identifies two distinctive subgroups of cancers: impact on cancer risk and survival in patients with myositis. Rheumatology (Oxford) 55(9):1631–1641CrossRef
11.
go back to reference Yang H, Peng Q, Yin L, Li S, Shi J, Zhang Y, Lu X, Shu X, Zhang S, Wang G (2017) Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study. Arthritis Res Ther 19(1):259CrossRef Yang H, Peng Q, Yin L, Li S, Shi J, Zhang Y, Lu X, Shu X, Zhang S, Wang G (2017) Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study. Arthritis Res Ther 19(1):259CrossRef
12.
go back to reference Ponyi A, Constantin T, Garami M, Andras C, Tallai B, Vancsa A et al (2005) Cancer-associated myositis: clinical features and prognostic signs. Ann N Y Acad Sci 1051:64–71CrossRef Ponyi A, Constantin T, Garami M, Andras C, Tallai B, Vancsa A et al (2005) Cancer-associated myositis: clinical features and prognostic signs. Ann N Y Acad Sci 1051:64–71CrossRef
13.
go back to reference Andras C, Ponyi A, Constantin T, Csiki Z, Szekanecz E, Szodoray P et al (2008) Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol 35(3):438–444PubMed Andras C, Ponyi A, Constantin T, Csiki Z, Szekanecz E, Szodoray P et al (2008) Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol 35(3):438–444PubMed
14.
go back to reference Wakata N, Kurihara T, Saito E, Kinoshita M (2002) Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol 41(11):729–734CrossRef Wakata N, Kurihara T, Saito E, Kinoshita M (2002) Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol 41(11):729–734CrossRef
15.
go back to reference Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, Evans SR, Felson DT (2001) Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet (London, England) 357(9250):96–100CrossRef Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, Evans SR, Felson DT (2001) Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet (London, England) 357(9250):96–100CrossRef
16.
go back to reference Chen YJ, Wu CY, Huang YL, Wang CB, Shen JL, Chang YT (2010) Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan. Arthritis Res Ther 12(2):R70CrossRef Chen YJ, Wu CY, Huang YL, Wang CB, Shen JL, Chang YT (2010) Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan. Arthritis Res Ther 12(2):R70CrossRef
17.
go back to reference Kim JA, Yoon S, Kim LY, Kim DS (2017) Towards actualizing the value potential of Korea Health Insurance Review and Assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data. J Korean Med Sci 32(5):718–728CrossRef Kim JA, Yoon S, Kim LY, Kim DS (2017) Towards actualizing the value potential of Korea Health Insurance Review and Assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data. J Korean Med Sci 32(5):718–728CrossRef
18.
go back to reference National Health Insurance Corporation HIPRI (2010) Research report on health care utilization of patients with rare and intractable disorder and improvement of individual copayment beneficiaries program for rare and intractable disorder (in Korean) National Health Insurance Corporation HIPRI (2010) Research report on health care utilization of patients with rare and intractable disorder and improvement of individual copayment beneficiaries program for rare and intractable disorder (in Korean)
19.
go back to reference Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292(7):344–347CrossRef Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292(7):344–347CrossRef
20.
go back to reference Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292(8):403–407CrossRef Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292(8):403–407CrossRef
21.
go back to reference Elixhauser A, Steiner C, Harris DR, Coffey RM (1998) Comorbidity measures for use with administrative data. Med Care 36(1):8–27CrossRef Elixhauser A, Steiner C, Harris DR, Coffey RM (1998) Comorbidity measures for use with administrative data. Med Care 36(1):8–27CrossRef
22.
go back to reference Seo HJ, Oh IH, Yoon SJ (2012) A comparison of the cancer incidence rates between the national cancer registry and insurance claims data in Korea. Asian Pac J Cancer Prev 13(12):6163–6168CrossRef Seo HJ, Oh IH, Yoon SJ (2012) A comparison of the cancer incidence rates between the national cancer registry and insurance claims data in Korea. Asian Pac J Cancer Prev 13(12):6163–6168CrossRef
23.
go back to reference Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senecal JL (2005) Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 84(4):231–249CrossRef Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senecal JL (2005) Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 84(4):231–249CrossRef
24.
go back to reference Dobloug GC, Svensson J, Lundberg IE, Holmqvist M (2018) Mortality in idiopathic inflammatory myopathy: results from a Swedish nationwide population-based cohort study. Ann Rheum Dis 77(1):40–47CrossRef Dobloug GC, Svensson J, Lundberg IE, Holmqvist M (2018) Mortality in idiopathic inflammatory myopathy: results from a Swedish nationwide population-based cohort study. Ann Rheum Dis 77(1):40–47CrossRef
25.
go back to reference Torres C, Belmonte R, Carmona L, Gomez-Reino FJ, Galindo M, Ramos B et al (2006) Survival, mortality and causes of death in inflammatory myopathies. Autoimmunity 39(3):205–215CrossRef Torres C, Belmonte R, Carmona L, Gomez-Reino FJ, Galindo M, Ramos B et al (2006) Survival, mortality and causes of death in inflammatory myopathies. Autoimmunity 39(3):205–215CrossRef
26.
go back to reference Maldonado F, Patel RR, Iyer VN, Yi ES, Ryu JH (2012) Are respiratory complications common causes of death in inflammatory myopathies? An autopsy study. Respirology (Carlton, Vic) 17(3):455–460CrossRef Maldonado F, Patel RR, Iyer VN, Yi ES, Ryu JH (2012) Are respiratory complications common causes of death in inflammatory myopathies? An autopsy study. Respirology (Carlton, Vic) 17(3):455–460CrossRef
27.
go back to reference Woo JH, Kim YJ, Kim JJ, Choi CB, Sung YK, Kim TH, Jun JB, Bae SC, Yoo DH (2013) Mortality factors in idiopathic inflammatory myopathy: focusing on malignancy and interstitial lung disease. Mod Rheumatol 23(3):503–508CrossRef Woo JH, Kim YJ, Kim JJ, Choi CB, Sung YK, Kim TH, Jun JB, Bae SC, Yoo DH (2013) Mortality factors in idiopathic inflammatory myopathy: focusing on malignancy and interstitial lung disease. Mod Rheumatol 23(3):503–508CrossRef
28.
go back to reference Registry KCC (2011) Annual report of cancer statistics in Korea in 2010. Ministry for Health and Welfare, Korean National Cancer Institute Goyang Registry KCC (2011) Annual report of cancer statistics in Korea in 2010. Ministry for Health and Welfare, Korean National Cancer Institute Goyang
29.
go back to reference Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386CrossRef Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386CrossRef
30.
go back to reference Choi J, Han S, Kim N, Lim YS (2017) Increasing burden of liver cancer despite extensive use of antiviral agents in a hepatitis B virus-endemic population. Hepatology (Baltimore, Md) 66(5):1454–1463CrossRef Choi J, Han S, Kim N, Lim YS (2017) Increasing burden of liver cancer despite extensive use of antiviral agents in a hepatitis B virus-endemic population. Hepatology (Baltimore, Md) 66(5):1454–1463CrossRef
31.
go back to reference Dutton K, Soden M (2017) Malignancy screening in autoimmune myositis among Australian rheumatologists. Intern Med J 47(12):1367–1375CrossRef Dutton K, Soden M (2017) Malignancy screening in autoimmune myositis among Australian rheumatologists. Intern Med J 47(12):1367–1375CrossRef
32.
go back to reference Ceribelli A, Isailovic N, De Santis M, Generali E, Fredi M, Cavazzana I et al (2017) Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis. Clin Rheumatol 36(2):469–475CrossRef Ceribelli A, Isailovic N, De Santis M, Generali E, Fredi M, Cavazzana I et al (2017) Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis. Clin Rheumatol 36(2):469–475CrossRef
33.
go back to reference Hida A, Yamashita T, Hosono Y, Inoue M, Kaida K, Kadoya M, Miwa Y, Yajima N, Maezawa R, Arai S, Kurasawa K, Ito K, Shimada H, Iwanami T, Sonoo M, Hatanaka Y, Murayama S, Uchibori A, Chiba A, Aizawa H, Momoo T, Nakae Y, Sakurai Y, Shiio Y, Hashida H, Yoshizawa T, Sakiyama Y, Oda A, Inoue K, Takeuchi S, Iwata NK, Date H, Masuda N, Mikata T, Motoyoshi Y, Uesaka Y, Maeda MH, Nakashima R, Tsuji S, Kwak S, Mimori T, Shimizu J (2016) Anti-TIF1-gamma antibody and cancer-associated myositis: a clinicohistopathologic study. Neurology 87(3):299–308CrossRef Hida A, Yamashita T, Hosono Y, Inoue M, Kaida K, Kadoya M, Miwa Y, Yajima N, Maezawa R, Arai S, Kurasawa K, Ito K, Shimada H, Iwanami T, Sonoo M, Hatanaka Y, Murayama S, Uchibori A, Chiba A, Aizawa H, Momoo T, Nakae Y, Sakurai Y, Shiio Y, Hashida H, Yoshizawa T, Sakiyama Y, Oda A, Inoue K, Takeuchi S, Iwata NK, Date H, Masuda N, Mikata T, Motoyoshi Y, Uesaka Y, Maeda MH, Nakashima R, Tsuji S, Kwak S, Mimori T, Shimizu J (2016) Anti-TIF1-gamma antibody and cancer-associated myositis: a clinicohistopathologic study. Neurology 87(3):299–308CrossRef
Metadata
Title
Temporal relationship between idiopathic inflammatory myopathies and malignancies and its mortality: a nationwide population-based study
Authors
Yoon-Kyoung Sung
Sun-Young Jung
Hyoungyoung Kim
Seongmi Choi
Seul Gi Im
Eom Ji Cha
Eun Jin Jang
Dae-Hyun Yoo
Soo-Kyung Cho
Publication date
01-11-2020
Publisher
Springer International Publishing
Published in
Clinical Rheumatology / Issue 11/2020
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-019-04782-0

Other articles of this Issue 11/2020

Clinical Rheumatology 11/2020 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.